Clinical Trials Browser

INDUSTRY × NSCLC × Clear all

NCT05378763 2026-05-22

PINNACLE

Phase 3 Suspended

NSCLC

NCT07376382 2026-05-13

SYNSTAR-02

Phase 3 Not yet recruiting

NSCLC

NCT05636267 2026-03-09

Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients

Phase 1/2 Terminated

NSCLC

NCT07169552 2025-12-17

HC010 in First-line PD-L1 Positive Advanced NSCLC Patients

Phase 2 Recruiting

NSCLC

NCT04858958 2025-11-19

FAVOUR

Phase 1 Active not recruiting

NSCLC

NCT05466149 2025-11-19

Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion

Phase 2 Active not recruiting

NSCLC

NCT07181499 2025-09-30

Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI

Phase 2 Recruiting

NSCLC

NCT06754644 2025-06-10

A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC

Phase 3 Recruiting

NSCLC

NCT04820023 2025-06-06

Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment

Phase 1/2 Terminated

45 enrolled 19 charts

NSCLC

NCT06940401 2025-05-14

JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations

Phase 1/2 Recruiting

NSCLC

NCT05994131 2025-04-30

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

Phase 1/2 Recruiting

NSCLC

NCT02973763 2025-04-03

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Alflutinib in Advanced Non Small Cell Lung Cancer

Phase 1 Terminated

NSCLC

NCT04958967 2025-03-14

Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation

Phase 1 Withdrawn

NSCLC

NCT06672068 2024-12-30

A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC

Phase 2 Not yet recruiting

NSCLC

NCT06739031 2024-12-18

Clinical Trial to Evaluate the Efficacy and Safety of Pulsed Electric Field Ablation Devices in the Treatment of Lung Tumors

Phase NA Not yet recruiting

NSCLC

NCT06247280 2024-12-06

Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR Mutation

Active not recruiting

NSCLC

NCT05383898 2024-10-15

Study to Evaluate D-1553 in Subjects With Lung Cancer

Phase 1/2 Completed

NSCLC

NCT05492045 2024-10-15

A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer

Phase 1/2 Terminated

NSCLC

NCT03866499 2024-08-07

A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients

Phase 3 Active not recruiting

NSCLC

NCT05987345 2024-07-22

Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung Cancer

Phase NA Recruiting

NSCLC

NCT04402008 2024-06-25

Study of Poziotinib in Japanese Patients With NSCLC

Phase 1/2 Terminated

42 enrolled 16 charts

NSCLC

NCT05493501 2024-05-02

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Phase 3 Terminated

8 enrolled 7 charts

NSCLC

NCT03318939 2024-04-03

Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Phase 2 Terminated

NSCLC

NCT05382728 2024-01-30

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

Phase 3 Recruiting

NSCLC

NCT04204473 2023-11-18

A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive Mutation

Phase 1 Completed

NSCLC

NCT05693090 2023-03-06

Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer

Phase 1 Withdrawn

NSCLC

NCT05651269 2022-12-15

Milciclib in Combination With Gemcitabine in Advanced NSCLC

Phase 2 Unknown

NSCLC

NCT05332574 2022-08-05

A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor

Phase 1/2 Unknown

Other solid neoplasmThoracic

NSCLC

NCT05117658 2022-08-04

Study of HA121-28 in Patients With Non-Small Cell Lung Cancer

Phase 2 Unknown

NSCLC

NCT03812809 2022-05-19

A Phase IIb Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients With T790M Mutation Positive

Phase 2 Completed

NSCLC

NCT03562871 2022-04-21

IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC

Phase 1/2 Completed

NSCLC

NCT05065398 2022-01-21

A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 Mutation

Phase 2 Unknown

NSCLC

NCT04874844 2021-05-10

JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety

Phase 2/3 Unknown

NSCLC

NCT04390984 2021-01-11

Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients

Phase 1 Unknown

NSCLC

NCT04044170 2020-11-17

Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

Phase 2 Terminated

NSCLC

NCT00576225 2020-10-19

CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL

Phase 3 Withdrawn

NSCLC

NCT04413227 2020-06-02

A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors

Phase 1 Unknown

Other solid neoplasmThoracic

NSCLC

NCT02976116 2019-11-15

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

Phase 2 Completed

NSCLC

NCT02691299 2019-02-12

FALUCA

Phase 3 Completed

NSCLC

NCT03453307 2018-03-05

Drug Sensitivity Correlation Between Patient-Derived Organoid Model and Clinical Response in NSCLC Patients

NSCLC

NCT02404675 2017-07-28

INCREASE

Phase 4 Unknown

NSCLC

NCT00874848 2016-11-29

Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

90 enrolled 20 charts

NSCLC

NCT00683514 2016-10-04

Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer

Phase 3 Completed

NSCLC

NCT00259064 2016-06-02

INSTEP

Phase 2/3 Completed

NSCLC

NCT00655161 2014-01-29

A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation

Phase 2 Completed

NSCLC

NCT00072618 2011-10-20

Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) Patients

Phase 1/2 Completed

NSCLC

NCT00283634 2011-02-17

A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer

Phase 2 Terminated

NSCLC